for Temporary Mechanical
Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock.
Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of the heart and enabling patients to undergo necessary interventional procedures.
Patients with coronary artery disease (CAD) often require interventions such as angioplasty or stenting. Many patients with advanced disease or complicating comorbidities are not able to undergo percutaneous coronary interventional (PCI) procedures without the use of temporary support from a pVAD.
Patients that have a severe heart attack can suffer from cardiogenic shock (CS). During CS, a patient’s heart is too weak to adequately pump blood to vital organs and a pVAD may be required.
Next Generation Solution for Temporary Mechanical Circulatory Support
High-flow from a low-profile catheter pump designed to minimize vascular complications
Aiming to provide real-time, accurate monitoring of pump performance and location
Robust platform intended to address both high-risk PCI and cardiogenic shock patients
Supira Medical, Inc. is a portfolio company of Shifamed, LLC., a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.
VP of Quality
Vice President, Intellectual Property
Sr. VP, HR & Administration
Interested in joining the team?
View open positions with Supira Medical and Shifamed’s portfolio companies.
Note: Principals only. No third-party referrals will be accepted without prior approval by Shifamed. As a general practice, Shifamed does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.
Novel Percutaneous Ventricular Assist Device Feasible in Patients Undergoing High-Risk Percutaneous Coronary Interventions (HRPCI)
First-of-its-Kind Low Profile, High Continuous Flow Device May Reduce Risk of Vascular Complications Associated with Current Devices
Supira Medical’s Percutaneous Ventricular Assist Device (pVAD) to be Highlighted During PCR Innovator’s Day and SCAI 2023
Supira’s technology features a novel low profile, high continuous flow design that aims to provide full hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients with a single device. Data from the Company’s First-in-Human trial to be presented as part of the Late-Breaking Clinical Research Session at SCAI 2023
Los Gatos, Calif., May 12, 2023 – Supira Medical, Inc., a Shifamed portfolio company, announced today that its next generation percutaneous ventricular assist device (pVAD) was selected following a highly competitive review process to be highlighted as part of this year’s European Association of Percutaneous Cardiovascular Interventions conference (EuroPCR) Innovator’s Day in Paris, France. Gagan Singh M.D., M.S., Director of Clinical Cardiovascular Research at University of California, Davis, will present on behalf of the company during the “Innovations in Heart Failure: Pumps, Remodeling and Monitoring” session beginning at 12:05 pm CET on Monday, May 15th in the Theatre Havane of the Palais de Congrès. Additionally, Supira Medical will be at booth M23 where PCR attendees can learn more about the system.
Supira Medical Announces Successful First-In-Human Use Of Its Next Generation Percutaneous Ventricular Assist Device
Three leading U.S. interventional cardiologists attend initial cases as company prepares to expand its clinical program
Los Gatos, Calif., September 16, 2022 – Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay. The prospective, single-arm, single-center study will evaluate the safety and performance of Supira’s low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).
Supira Medical, A Shifamed Portfolio Company, Closes $30m in an Oversubscribed Series C Financing
Company to Advance its Next Generation Percutaneous Ventricular Assist Device
Los Gatos, Calif., February 28, 2022 – Supira Medical, Inc., a Shifamed portfolio company that is focused on developing a next-generation solution for temporary mechanical circulatory support, announced today the closing of $30M in Series C financing. Led by Cormorant Asset Management and The Capital Partnership (TCP), with participation from 415 CAPITAL, AMED Ventures, PA MedTech VC Fund and Shifamed angel investors, the funds will be used to finalize product development and initiate a first-in-human clinical study for the company’s high-flow, low-profile percutaneous ventricular assist device (pVAD).
Supira Medical, A Shifamed Portfolio Company, Closes $35M in Series B Financing
Company Appoints Seasoned Medtech Executive as President and CEO
CAMPBELL, Calif., March 5, 2020 – Supira Medical, formed by Shifamed as part of its medical innovation hub, announced today the closing of $35M in Series B financing. Officially closed on February 25, the financing was led by Cormorant Asset Management with participation from The Capital Partnership (TCP), 415 CAPITAL, AMED Ventures and Shifamed Angels. The funds will be used to advance product development and clinical efforts for the company’s next generation percutaneous ventricular assist device (pVAD). Additionally, the company announced the appointment of seasoned medical device executive, Dr. Nitin Salunke, as President and Chief Executive Officer.